20/20 GeneSystems, Inc.
ROCKVILLE, MARYLAND – December 29, 2005 – 20/20 GeneSystems, Inc. (20/20) has been issued US Patent # 6,958,242, the second patent to cover the technology employed in the company’s BioCheck™ Powder Screening Kit. This patent has very broad claims that cover not only the specific chemistries employed in the BioCheck product but also its underlying testing methodology.
“Strong intellectual property protection along with exceptional quality and innovation is helping 20/20 become a market leader within the first responder community” said Jonathan Cohen, President and CEO of 20/20.
The BioCheck Powder Screening Test kit is used by more than 300 first responder organizations to screen suspicious powders for bioterrorism agents. Users of the product include fire departments in major jurisdictions and a dozen federal agencies. The BioCheck Kit provides a rapid screen for the possible presence of multiple bioterrorism agents (for example, anthrax and ricin toxin) while ruling out most of the ordinary substances that citizens have frequently feared to be possible weapons of mass destruction (WMDs).
The product requires no instrumentation and helps first responders determine in five minutes or less whether testing for one or more specific pathogens or toxins is warranted.
About 20/20 GeneSystems
20/20 GeneSystems was founded in 2000 and is based in Rockville, Maryland. The company develops and markets innovative diagnostics products for homeland security, oncology and immunology.